Antitumor effects of a new lipophilic platinum compound, trans-bis(n-valerato)(1R,2R-cyclohexanediamine)(oxalato)platinum(IV), in mice

A new lipophilic platinum (Pt) compound, trans-bis (n-valerato) (1R, 2R-cyc lohexanediamine) (oxala to)Pt(lV) (C5-OHP), was compared with cisplatin (CD DP) by intra-peritoneal injection for antitumor activities against 3 differ ent mouse models, L1210 leukemia, LMFS sarcoma with high metastatic potenti al and spontaneous mammary turner C5-OHP cured both CDDP-sensitive and -res istant L1210 leukemia frequently. CDDP did not cute the leukemia, although it prolonged the survival of diseased mice significantly. C5-OHP cured earl y and advanced LMFS sarcomas more frequently than CDDP. Cured mice had acqu ired antitumor immunity, indicating the pivotal role of the immune system i n induction of the cure of tumors. it is likely that C5-OHP can eradicate t urner cells more effectively than CDDP by virtue of its weaker suppressive effects on the immune system. C5-OHP but nor CDDP could cure mammary tumors . C5-OHP manifested a curative effect against LMFS tumors by oral route. Th ese results indicate that C5-OHP is a promising anticancer agent worthy of clinical trial.